Format

Send to

Choose Destination
Am J Transplant. 2016 Jul;16(7):2117-38. doi: 10.1111/ajt.13710. Epub 2016 Mar 15.

Calcineurin Inhibitor Minimization, Conversion, Withdrawal, and Avoidance Strategies in Renal Transplantation: A Systematic Review and Meta-Analysis.

Author information

1
Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
2
Department of Pharmacy Services, Hospital of the University of Pennsylvania, Philadelphia, PA.
3
Center for Evidence-based Practice, University of Pennsylvania Health System, Philadelphia, PA.
4
ECRI Institute, Plymouth Meeting, PA.
5
Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.

Abstract

Despite their clinical efficacy, concerns about calcineurin inhibitor (CNI) toxicity make alternative regimens that reduce CNI exposure attractive for renal transplant recipients. In this systematic review and meta-analysis, we assessed four CNI immunosuppression strategies (minimization, conversion, withdrawal, and avoidance) designed to reduce CNI exposure and assessed the impact of each on patient and allograft survival, acute rejection and renal function. We evaluated 92 comparisons from 88 randomized controlled trials and found moderate- to high-strength evidence suggesting that minimization strategies result in better clinical outcomes compared with standard-dose regimens; moderate-strength evidence indicating that conversion to a mammalian target of rapamycin inhibitor or belatacept was associated with improved renal function but increased rejection risk; and moderate- to high-strength evidence suggesting planned CNI withdrawal could result in improved renal function despite an association with increased rejection risk. The evidence base for avoidance studies was insufficient to draw meaningful conclusions. The applicability of the review is limited by the large number of studies examining cyclosporine-based strategies and low-risk populations. Additional research is needed with tacrolimus-based regimens and higher risk populations. Moreover, research is necessary to clarify the effect of induction and adjunctive agents in alternative immunosuppression strategies and should include more comprehensive and consistent reporting of patient-centered outcomes.

KEYWORDS:

calcineurin inhibitor (CNI); clinical research/practice; health services and outcomes research; immunosuppressant; immunosuppressive regimens; kidney transplantation/nephrology

PMID:
26990455
DOI:
10.1111/ajt.13710
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center